Edition:
United States

Neovacs SA (ALNEV.PA)

ALNEV.PA on Paris Stock Exchange

0.54EUR
11:35am EST
Change (% chg)

€-0.01 (-1.82%)
Prev Close
€0.55
Open
€0.55
Day's High
€0.55
Day's Low
€0.54
Volume
240,403
Avg. Vol
400,605
52-wk High
€1.12
52-wk Low
€0.50

Chart for

About

Neovacs SA is a France-based company active in the biotechnology industry. It specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The Company researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The Company... (more)

Overall

Beta: 0.61
Market Cap(Mil.): €33.88
Shares Outstanding(Mil.): 61.61
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 200.64 15.49
EPS (TTM): -- -- --
ROI: -- -10.01 11.95
ROE: -- -35.77 15.94

BRIEF-Neovacs H1 net loss widens to 8.1‍​ million euros

* H1 NET LOSS EUR 8.1‍​ MILLION VERSUS LOSS OF EUR 6.8 MILLION YEAR AGO

Oct 27 2017

France's Neovacs takes on GSK and AstraZeneca in battle to treat lupus

PARIS French biotech company Neovacs is confident that its experimental drug to treat lupus could grab significant market share from standard treatments of the auto-immune disease, its chief executive said.

Sep 15 2017

France's Neovacs takes on GSK and AstraZeneca in battle to treat lupus

PARIS, Sept 15 French biotech company Neovacs is confident that its experimental drug to treat lupus could grab significant market share from standard treatments of the auto-immune disease, its chief executive said.

Sep 15 2017

BRIEF-Neovacs raises EUR 6.0 million in private placement with U.S. biotechnology institutional investors

* REG-NEOVACS: SUCCESSFULLY RAISES €6.0 MILLION IN PRIVATE PLACEMENT WITH U.S. BIOTECHNOLOGY INSTITUTIONAL INVESTORS

Jul 31 2017

BRIEF-Neovacs announces FDA acceptance of new IND to expand Ifnalpha Kinoid clinical development program in dermatomyositis

* REG-NEOVACS ANNOUNCES FDA ACCEPTANCE OF A NEW IND TO EXPAND IN U.S. IFNALPHA KINOID CLINICAL DEVELOPMENT PROGRAM IN DERMATOMYOSITIS

Jul 19 2017

BRIEF-Neovacs syas phase IIb trial Ifnalpha Kinoid in Lupus gets positive IDSMB review

* REG-NEOVACS ANNOUNCES POSITIVE IDSMB REVIEW FOR PHASE IIB CLINICAL TRIAL OF IFNALPHA KINOID IN LUPUS

Jul 11 2017

BRIEF-Neovacs announces license agreement for Ifnalpha Kinoid for treatment of lupus in Turkey

* REG-NEOVACS ANNOUNCES LICENSE AGREEMENT FOR IFNALPHA KINOID FOR TREATMENT OF LUPUS IN TURKEY

Jul 05 2017

BRIEF-Neovacs completes patient enrollment in phase IIb clinical study of IFNalpha kinoid

* NEOVACS ANNOUNCES THE COMPLETION OF PATIENT ENROLLMENT IN PHASE IIB CLINICAL STUDY OF IFNALPHA KINOID IN LUPUS

Jun 20 2017

BRIEF-Neovacs raises 3.7 million euros by issuing 4.6 million shares

* RAISES EUR 3.7 MILLION BY ISSUING 4.6 MILLION SHARES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jun 01 2017

Earnings vs. Estimates